Background: Small intestinal bacterial overgrowth (SIBO) has been proposed to be common in irritable bowel syndrome (IBS), with altered small-bowel motility as a possible predisposing factor.
Aim: To assess the prevalence of SIBO, by culture of small-bowel aspirate, and its correlation to symptoms and motility in IBS.
Methods: 162 patients with IBS who underwent small-bowel manometry and culture of jejunal aspirate were included. Cultures from 26 healthy subjects served as controls. Two definitions of altered flora were used: the standard definition of SIBO (>/=10(5) colonic bacteria/ml), and mildly increased counts of small-bowel bacteria (>/=95th centile in controls).
Results: SIBO (as per standard definition) was found in 4% of both patients and controls. Signs of enteric dysmotility were seen in 86% of patients with SIBO and in 39% of patients without SIBO (p = 0.02). Patients with SIBO had fewer phase III activities (activity fronts) than patients without SIBO (p = 0.08), but otherwise no differences in motility parameters were seen. Mildly increased bacterial counts (>/=5x10(3)/ml) were more common in patients with IBS than in controls (43% vs 12%; p = 0.002), but this was unrelated to small intestinal motility. No correlation between bacterial alterations and symptom pattern was observed.
Conclusions: The data do not support an important role for SIBO according to commonly used clinical definitions, in IBS. However, mildly increased counts of small-bowel bacteria seem to be more common in IBS, and needs further investigation. Motility alterations could not reliably predict altered small-bowel bacterial flora.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1954873 | PMC |
http://dx.doi.org/10.1136/gut.2006.108712 | DOI Listing |
Dig Dis Sci
December 2024
Gastrointestinal Motility Laboratory, Department of Gastroenterology, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico D.F., Mexico.
Background: Irritable bowel syndrome symptoms are associated with diverse pathophysiological mechanisms including small intestinal bacterial overgrowth and food intolerance. Small intestinal bacterial overgrowth leads to the decreased activity of several digestive enzymes, including lactase.
Aims: To assess the efficacy of rifaximin-alpha on the symptoms and lactase activity of patients with irritable bowel syndrome without constipation.
Metabolic bariatric surgery is considered the most effective treatment for severe obesity, however it may be associated with the development of Small Intestinal Bacterial Overgrowth (SIBO) and other gastrointestinal symptoms (GIS). This study conducted a systematic review and meta-analysis to evaluate the effects of probiotics or synbiotics on GIS and SIBO in post- metabolic bariatric surgery patients. Five studies that investigated the effect of probiotics or synbiotics in the treatment of post-surgery GIS were included in the review, with three focusing on SIBO.
View Article and Find Full Text PDFNeurogastroenterol Motil
November 2024
Medical College of Georgia, Augusta University, Augusta, Georgia.
Background: There is a large unmet need for alternative, non-invasive, and accurate diagnosis of small intestinal bacterial overgrowth (SIBO). The smart capsule bacterial detection system (SCBDS) device contains a targeted sampling technology and an onboard SCBDS assay to detect metabolically active bacteria in the small intestine. Here, we evaluated the agreement of SCBDS assay with duodenal aspiration/culture ex vivo in a multicenter clinical study.
View Article and Find Full Text PDFCureus
October 2024
Department of Surgery, University of South Florida Morsani College of Medicine, Tampa, USA.
Small bowel diverticulosis can occur anywhere in the small bowel but is most common in the duodenum. Jejunoileal diverticulosis is much less common and tends to have a more chronic, nonspecific disease course. In the literature, this condition has a higher incidence in men in their sixth and seventh decades of life.
View Article and Find Full Text PDFRev Gastroenterol Peru
November 2024
Zacpharma, Medellín, Colombia.
Introduction: Conventional management of small intestinal bacterial overgrowth (SIBO) involves intraluminal-action antibiotics. Controversially, probiotics are used to optimize outcomes, but this therapeutic intervention is understudied.
Objective: To evaluate the efficacy of probiotics in the treatment of small intestinal bacterial overgrowth.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!